From: Systemic treatment for lung carcinoids: from bench to bedside
Systemic treatment | Study identifier | Study title | Study design | Population | Intervention | Primary endpoint |
---|---|---|---|---|---|---|
SSAs | NCT02683941 | SPINET | Phase 3 Randomized double-blind | TCs and ACs | Lanreotide + BSC vs PCB + BSC | DCR |
NCT02698410 | ATLANT | Phase 2 Single arm Open-label | TCs and ACs | Lanreotide + TMZ | PFS | |
NCT02823691 | MetNET-2 | Early Phase 1 | Advanced GI-NENs and lung carcinoids | Lanreotide + metformin | Safety | |
PRRT | NCT03466216 | – | Phase 1 | SSTRs positive advanced NENs | AlphaMedix™ | Safety and DLT |
NCT03273712 | – | Phase 2 Single arm Open-label | SSTRs positive advanced NENs | [Yttrium-90-DOTA]TOC | ORR and safety | |
NCT03454763 | LUTHREE | Phase 2 Randomized Open-label | SSTRs positive advanced NENs | [Lutetium-177-DOTA]TATE every 5 week (intensive) vs Lutetium-177-DOTA]TATE every 8–10 week (no intensive) | PFS and safety | |
NCT02754297 | P-PRRT | Phase 2 Single arm Open-label | SSTRs positive advanced NENs | [Lutetium-177-DOTA]TOC | ORR | |
Everolimus | NCT03629847 | – | Phase 1–2 Single arm Open-label | SSTRs positive advanced NENs | Everolimus + [Lutetium-177-DOTA]TATE | Safety |
NCT03670030 | – | Phase 2 Single arm Open-label | Advanced well differentiated NENs | ABI-009 | ORR | |
CHT | NCT02698410 | ATLANT | Phase 2 Single arm Open-label | TCs and ACs | Lanreotide + temozolomide | DCR |
NCT03217097 | MGMT-NET | Phase 4 Randomized Open-label | Advanced well differentiated lung, duodenopancreatic and unknown origin NENs | Oxaliplatin vs temozolomide | ORR |